<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Multifocal atrial tachycardia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Multifocal atrial tachycardia</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Multifocal atrial tachycardia</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alfred Buxton, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hugh Calkins, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 21, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Multifocal atrial tachycardia (MAT) is an arrhythmia that can be seen in a variety of clinical disorders [<a href="#rid1">1</a>]. In addition to a heart rate greater than 100 beats per minute (bpm), the characteristic electrocardiographic (ECG) feature is variability in P-wave morphology. Although this abnormality had been noted for many years during some types of atrial tachycardia, the term MAT became commonplace terminology in the late 1960s [<a href="#rid2">2</a>]. Patients with multiple P-wave morphologies but a normal heart rate (60 to 100 bpm) are considered to have a wandering atrial pacemaker, since the heart rate does not meet criteria for a tachycardia. (See <a class="local">'Terminology'</a> below.)</p><p>This topic will review the definition, pathogenesis, etiology, and treatment of MAT in adults. Other tachycardias of atrial origin, as well as the discussion of this arrhythmia in children, are reviewed separately. (See  <a class="medical medical_review" href="/d/html/900.html" rel="external">"Focal atrial tachycardia"</a> and  <a class="medical medical_review" href="/d/html/14407.html" rel="external">"Atrial tachyarrhythmias in children"</a> and  <a class="medical medical_review" href="/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a> and  <a class="medical medical_review" href="/d/html/976.html" rel="external">"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway"</a> and  <a class="medical medical_review" href="/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITION, PATHOGENESIS, AND PREVALENCE</span><span class="headingEndMark"> — </span>As with any tachycardia, the heart rate in MAT exceeds 100 bpm. To distinguish MAT from other tachyarrhythmias of atrial origin, there should be organized atrial activity yielding P waves with three or more different morphologies. (See <a class="local">'Clinical manifestations and diagnosis'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Terminology</span><span class="headingEndMark"> — </span>A number of authors have used the term "chaotic" to describe MAT [<a href="#rid3">3-5</a>]. However, chaos in modern usage in nonlinear dynamics and mathematics implies there is order in what appear to be random events [<a href="#rid6">6</a>]. A more accurate term for this arrhythmia is probably "multiform" as there is no proof that the arrhythmia is actually multifocal, although multifocal remains the commonly used term [<a href="#rid1">1</a>].</p><p>The tachycardic threshold for multifocal atrial tachycardia (MAT) has traditionally been set at 100 bpm, but a review of 60 patients with multifocal atrial arrhythmias found a stronger association between the incidence of COPD exacerbations and the diagnosis of MAT if a threshold of 90 bpm was used [<a href="#rid7">7</a>]. The definition of MAT also requires the presence of at least three distinct P-wave morphologies.</p><p>Some patients have similar ECG findings with multiple P-wave morphologies but do not meet criteria for tachycardia. The arrhythmia is called a multifocal atrial rhythm or wandering atrial pacemaker if the rate is between 60 and 100 bpm. A distinction has been made between the two based on the clinical picture, with a wandering atrial pacemaker usually occurring in the asymptomatic or less ill individual [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H4"><span class="h2">Mechanisms</span><span class="headingEndMark"> — </span>The changing morphology of the P waves and the variable PR interval suggests that the atrial pacemaker activity arises from different atrial locations. However, the variable PR interval is probably more likely a result of the variable atrial rate. Alternatively, a single focus with different exit pathways or abnormalities in intraatrial conduction could produce the identical ECG findings. There have only been a few invasive electrophysiologic investigations of MAT, but one study did show abnormal intraatrial, atrionodal, and atrioventricular (AV) nodal conduction in many individuals with MAT [<a href="#rid5">5</a>]. One case report demonstrated origin of multiform premature atrial complex (PACs; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat) from adjacent areas in the right pulmonary veins [<a href="#rid8">8</a>]. However, this patient did not have the typical setting in which MAT is seen.</p><p>Automaticity refers to normal, accelerated normal, or abnormal pacemaker activity. Triggered activity, on the other hand, results from a normal stimulus giving rise to afterdepolarization, which, if threshold is attained, can result in regenerative action potentials (resulting in tachycardia) in any cardiac tissue. Reentry refers to a circuit in which previously excited tissue is re-excited, producing an extra beat or a sustained rhythm. The occasional responsiveness of MAT to <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> suggests intracellular calcium overload causing afterdepolarizations leading to triggered activity as the underlying mechanism [<a href="#rid9">9,10</a>].</p><p>It is thought that MAT results from right atrial hypertension and distension, either from secondary pulmonary hypertension from advanced COPD or left ventricular dysfunction caused by comorbid processes such as coronary heart disease, systemic hypertension, or aortic stenosis [<a href="#rid11">11,12</a>]. However, although frequently associated with exacerbations of pulmonary disease, MAT may occur in other circumstances, so atrial distension may not be a universal mechanism.</p><p class="headingAnchor" id="H5"><span class="h2">Associated arrhythmias</span><span class="headingEndMark"> — </span>MAT (and wandering atrial pacemaker) is commonly accompanied by PACs and can itself be considered a prolonged sequence of PACs [<a href="#rid1">1</a>]. The majority of episodes of MAT are self-limited and nonsustained.</p><p>MAT may be associated with or precede atrial fibrillation [<a href="#rid2">2,13</a>]. In one report of 31 patients, for example, 55 percent developed atrial fibrillation or flutter [<a href="#rid14">14</a>].</p><p class="headingAnchor" id="H6"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>MAT is an uncommon but not rare arrhythmia. It has been estimated to occur in 0.05 to 0.32 percent of ECGs in general hospitals and in 0.37 percent of hospitalized patients [<a href="#rid1">1,2</a>]. The average age is approximately 70 years. These older adults are generally quite ill, with an in-hospital mortality rate of 40 to 60 percent due to pulmonary, cardiac, and other serious diseases.</p><p class="headingAnchor" id="H23843900"><span class="h1">ASSOCIATED CLINICAL CONDITIONS</span></p><p class="headingAnchor" id="H7"><span class="h2">Pulmonary disease</span><span class="headingEndMark"> — </span>MAT is associated with significant lung disease in roughly 60 percent of cases [<a href="#rid1">1,15</a>]. Furthermore, this arrhythmia has been identified in up to 20 percent of patients hospitalized for acute respiratory failure [<a href="#rid16">16</a>]. COPD is the most common pulmonary disorder associated with MAT, but this arrhythmia can also occur with pneumonia and pulmonary embolism. Hypoxia, hypercapnia, acidosis, autonomic imbalance, right atrial enlargement, and therapy with <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a>, <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, or <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a> all may contribute to the enhanced ectopic atrial activity [<a href="#rid2">2,9,17</a>] (see  <a class="medical medical_review" href="/d/html/1454.html" rel="external">"Arrhythmias in COPD"</a>).</p><p>MAT has also been identified in patients with coronavirus disease 2019 (COVID-19) [<a href="#rid18">18</a>]. In this setting, the presence of MAT was reported to not be associated with increased mortality<strong> </strong>[<a href="#rid18">18</a>]. (See  <a class="medical medical_review" href="/d/html/127551.html" rel="external">"COVID-19: Arrhythmias and conduction system disease"</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Cardiac disease</span><span class="headingEndMark"> — </span>MAT can occur in the presence of coronary, valvular, hypertensive and other types of heart disease, particularly when associated with heart failure and/or underlying lung disease. Affected patients tend to have elevated pulmonary capillary wedge and pulmonary end-diastolic pressures as well as a low-normal cardiac index [<a href="#rid2">2,13</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Interactions between cardiac and pulmonary disease</span><span class="headingEndMark"> — </span>In advanced cases of cardiac and pulmonary disease, MAT may be part of a complicated pathophysiologic complex in which several conditions (eg, pulmonary hypertension, elevated left ventricular filling pressures, and MAT) contribute to the progression and persistence of each other [<a href="#rid12">12,19,20</a>]. Illustrations of these relationships include:</p><p class="bulletIndent1"><span class="glyph">●</span>Severe pulmonary arterial hypertension has been associated with and may cause LV diastolic dysfunction [<a href="#rid19">19,20</a>]. (See  <a class="medical medical_review" href="/d/html/112486.html" rel="external">"Pulmonary hypertension due to left heart disease (group 2 pulmonary hypertension) in adults"</a> and  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/121912.html" rel="external">"Treatment and prognosis of pulmonary arterial hypertension in adults (group 1)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Theoretically, the rapid heart rate associated with MAT decreases diastolic filling time and can result in increased LV diastolic pressure, which in turn increases pulmonary artery pressure that encourages MAT [<a href="#rid12">12</a>]. However, the vast majority of episodes of MAT are brief and not associated with symptoms or recognizable hemodynamic compromise. (See  <a class="medical medical_review" href="/d/html/3504.html" rel="external">"Heart failure with preserved ejection fraction: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Prolonged episodes of tachycardia can cause a cardiomyopathy. (See  <a class="medical medical_review" href="/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Miscellaneous</span><span class="headingEndMark"> — </span>MAT is also associated with a number of other disorders:</p><p class="bulletIndent1"><span class="glyph">●</span>Hypokalemia – MAT has been associated with hypokalemia, most often induced by diuretic use [<a href="#rid1">1-3</a>]. Hypokalemia may predispose to MAT by increasing the rate of phase 4 depolarization  (<a class="graphic graphic_figure graphicRef64133" href="/d/graphic/64133.html" rel="external">figure 1</a>) in atrial tissues. (See  <a class="medical medical_review" href="/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults", section on 'Cardiac arrhythmias and ECG abnormalities'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hypomagnesemia – The administration of magnesium can suppress MAT in hypomagnesemic and, at times, in apparently normomagnesemic patients [<a href="#rid21">21</a>]. (See  <a class="medical medical_review" href="/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Drugs – As noted above, <a class="drug drug_general" data-topicid="8578" href="/d/drug information/8578.html" rel="external">isoproterenol</a>, <a class="drug drug_general" data-topicid="8620" href="/d/drug information/8620.html" rel="external">aminophylline</a>, and <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a> can induce or exacerbate MAT, particularly in the presence of pulmonary disease [<a href="#rid2">2,9,17</a>]. By comparison, digitalis is generally not considered to be a cause of MAT, although some reports suggest that such an association may exist [<a href="#rid2">2,3,13,14,22,23</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic renal failure – Approximately 15 percent of patients with MAT have chronic renal failure [<a href="#rid3">3,22</a>]. It is unclear, however, if this represents a cause-and-effect relationship.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other – MAT also can occur in sepsis and after recent surgery, particularly if the patient has pulmonary compromise and/or heart failure [<a href="#rid1">1,2</a>].</p><p></p><p class="headingAnchor" id="H11"><span class="h2">MAT in children and young adults</span><span class="headingEndMark"> — </span>The association of MAT with serious illness is generally less in children than in adults. Information on multifocal (or chaotic) atrial tachycardia in children is presented separately. (See  <a class="medical medical_review" href="/d/html/14407.html" rel="external">"Atrial tachyarrhythmias in children", section on 'Chaotic atrial tachycardia'</a>.)</p><p class="headingAnchor" id="H23844503"><span class="h1">CLINICAL MANIFESTATIONS AND DIAGNOSIS</span></p><p class="headingAnchor" id="H1314299656"><span class="h2">Clinical manifestations</span><span class="headingEndMark"> — </span>In most cases, the clinical manifestations of MAT differ from those of other tachyarrhythmias in that symptoms predominantly relate to the underlying precipitating illness rather than the arrhythmia [<a href="#rid15">15</a>]. Patients have an irregular heart rate greater than 100 bpm. The arrhythmia is usually recognized only by ECG monitoring, as the majority of patients are acutely ill and on continuous ECG monitoring. Patients rarely present with symptoms such as palpitations. Presyncope or syncope is generally not associated with this arrhythmia. Given that the majority of patients with MAT are concurrently affected by advanced or decompensated pulmonary disease, many patients have typical symptoms related to the underlying lung disease (eg, shortness of breath, wheezing, productive cough, etc) or acute metabolic derangements.</p><p>Most episodes of MAT do not precipitate hemodynamic compromise or limiting symptoms [<a href="#rid15">15</a>]. However, higher heart rates associated with MAT can sometimes worsen systemic oxygenation in patients with advanced pulmonary disease. Additionally, in patients with coexistent advanced cardiac disease, namely those with severe multivessel obstructive coronary artery disease or decompensated heart failure, the faster heart rates associated with MAT can exacerbate heart disease, leading to signs and symptoms of cardiac decompensation (eg, angina, dyspnea, orthopnea). Symptomatic decompensation of underlying cardiac or pulmonary disease is an indication for pharmacologic therapy aimed specifically at the tachycardia rather than therapy to control the underlying disease process. (See <a class="local">'Pharmacologic therapy'</a> below.)</p><p class="headingAnchor" id="H1228886218"><span class="h2">Diagnosis</span><span class="headingEndMark"> — </span>The diagnosis of MAT can be suspected from the presence of an irregular rapid pulse and heartbeat on physical examination, usually in a patient with underlying, often poorly controlled, cardiac or pulmonary disease. The diagnosis cannot be confirmed, however, without an ECG.</p><p>A diagnosis of MAT requires the following be present on the ECG  (<a class="graphic graphic_waveform graphicRef127222" href="/d/graphic/127222.html" rel="external">waveform 1</a>) [<a href="#rid1">1,2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Discrete P waves with at least <strong>three</strong> different morphologies (including the normal sinus P wave).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An atrial rate greater than 100 bpm, which is the classic definition of MAT [<a href="#rid2">2</a>]. However, based upon data from a series of patients with chronic obstructive pulmonary disease (COPD), a threshold of 90 bpm has been proposed [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>P waves that return to the baseline and thus are separated by isoelectric intervals.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>P-P intervals, P-R duration, and R-R intervals that vary. It should be recognized that the primary abnormality is the variability in P-P intervals. The variation in P-R intervals follows because of the physiologic response of the AV node to changing atrial rate. The variation in R-R intervals follows as a physiologic consequence of the variation in the P-P and P-R intervals.</p><p></p><p class="headingAnchor" id="H1117337"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>The differential diagnosis for MAT is similar to that of other narrow QRS complex tachycardias with an irregular rhythm (assuming there is normal AV conduction without bundle branch block) and includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Sinus tachycardia with frequent PACs or ventricular premature beats (VPBs)</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial tachycardias (including atrial flutter) with variable AV conduction</p><p class="bulletIndent1"><span class="glyph">●</span>Atrial fibrillation</p><p></p><p>MAT can usually be differentiated from both atrial flutter with variable AV conduction and sinus tachycardia with APBs/VPBs by the regular P-P interval seen in both atrial flutter and sinus tachycardia, which is not present in MAT. (See  <a class="medical medical_review" href="/d/html/1061.html" rel="external">"Electrocardiographic and electrophysiologic features of atrial flutter", section on 'Electrocardiographic features'</a>.)</p><p>MAT, with its organized atrial activity resulting in P waves on surface ECG, can be readily distinguished from atrial fibrillation, which lacks any discernible P waves. However, MAT can and does degenerate into atrial fibrillation in some patients. (See  <a class="medical medical_review" href="/d/html/1014.html" rel="external">"The electrocardiogram in atrial fibrillation"</a>.)</p><p>A more in-depth discussion of the differential diagnosis of narrow QRS complex tachycardias is presented separately. (See  <a class="medical medical_review" href="/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p class="headingAnchor" id="H754560"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Most episodes of MAT do not precipitate hemodynamic compromise or symptoms. Thus, therapy in patients with MAT should be aimed at the inciting underlying disease [<a href="#rid15">15,24,25</a>]. Amelioration of MAT generally parallels improvement in severe pulmonary or cardiac disease or sepsis. Not infrequently, medication used for the treatment of pulmonary disease, such as <a class="drug drug_general" data-topicid="10281" href="/d/drug information/10281.html" rel="external">theophylline</a>, induces or exacerbates MAT [<a href="#rid2">2,9,17</a>]. In many cases, MAT is precipitated by poor oxygenation and/or acid-base disturbances.</p><p>In addition to treatment for the underlying pathologic condition associated with MAT, specific therapies for the tachycardia are sometimes used (usually only if the arrhythmia is so frequent or sustained as to compromise oxygenation or cause hemodynamic compromise). In patients with electrolyte disturbances, maintaining magnesium and potassium levels in the normal range is important. Pharmacologic therapy to slow the ventricular heart rate, using either <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> or a beta blocker, is administered for patients with signs or symptoms felt to be related to their tachycardia. While rate control therapy is often very effective, there is no role for electrical cardioversion or antiarrhythmic drug therapy in patients with MAT.</p><p class="headingAnchor" id="H754567"><span class="h2">Magnesium and potassium repletion</span><span class="headingEndMark"> — </span>Patients with MAT and associated hypokalemia or hypomagnesemia should undergo electrolyte repletion prior to the initiation of additional medical therapy for MAT [<a href="#rid24">24</a>].</p><p>Hypomagnesemia appears to promote the development of some atrial and ventricular arrhythmias. The administration of magnesium has been reported to suppress MAT in the hypomagnesemic patient and, at times, in patients with normal plasma magnesium levels [<a href="#rid21">21,26</a>]. As an example, one study randomized 14 patients with chronic obstructive pulmonary disease and MAT to magnesium therapy (2 grams over five minutes and 10 grams over five hours) or placebo [<a href="#rid26">26</a>]. At five hours, patients treated with magnesium had a slowing of heart rate from 130 to 99 bpm, while there was no change in the placebo group. Sinus rhythm was present at the end of the infusion in seven of nine patients treated with magnesium versus one of five receiving placebo. (See  <a class="medical medical_review" href="/d/html/848.html" rel="external">"Hypomagnesemia: Clinical manifestations of magnesium depletion"</a>.)</p><p>Mild hypomagnesemia (serum magnesium 1.4 to 1.7 mg/dL) can be treated with 240 mg of elemental magnesium orally twice per day as <a class="drug drug_general" data-topicid="9583" href="/d/drug information/9583.html" rel="external">magnesium oxide</a> (400 mg twice daily) or a delayed release <a class="drug drug_general" data-topicid="10122" href="/d/drug information/10122.html" rel="external">magnesium chloride</a> preparation. Dose-dependent diarrhea occurs frequently. More significant hypomagnesemia (serum magnesium &lt;1.4 mg/dL) can be treated with 1 gram (8 mEq) of <a class="drug drug_general" data-topicid="9585" href="/d/drug information/9585.html" rel="external">magnesium sulfate</a> given intravenously over 15 minutes, followed by a continuous infusion of 3 to 6 grams (24 to 48 mEq) over 24 hours, OR as repeated intermittent infusions, each consisting of 1 gram over one hour, for a total of 3 to 6 grams over 12 hours. Because magnesium distributes gradually to tissues, early serum levels can appear artificially high, and repletion may require several days of treatment. The dose should be reduced by approximately 50 percent with even mild renal insufficiency. Response to the initial dose may give an indication of whether the MAT will be responsive to magnesium therapy. (Conversion relationships: 1 mmol = 2 mEq = 24 mg of elemental magnesium.)</p><p>Potassium repletion in the hypokalemic patient may also control MAT, with or without magnesium supplementation [<a href="#rid21">21,27</a>]. In an observational study of eight patients, the combined use of magnesium and potassium was associated with conversion to sinus rhythm in seven [<a href="#rid21">21</a>].</p><p>Potassium depletion can be treated with <a class="drug drug_general" data-topicid="9795" href="/d/drug information/9795.html" rel="external">potassium chloride</a> given either orally (20 to 60 mEq per day in divided doses if &gt;40 mEq) or intravenously (generally up to 10 mEq per hour, but occasionally at an initial rate of as much as 40 mEq per hour with severe hypokalemia with continuous echocardiogram monitoring). The patient's serum potassium should be carefully monitored to avoid hyperkalemia. Over the long-term, the cause of potassium loss should also be treated, (eg, the administration of a potassium-sparing diuretic to patients treated with loop or thiazide diuretics). (See  <a class="medical medical_review" href="/d/html/2297.html" rel="external">"Clinical manifestations and treatment of hypokalemia in adults"</a>.)</p><p class="headingAnchor" id="H754574"><span class="h2">Pharmacologic therapy</span><span class="headingEndMark"> — </span>The use of antiarrhythmic drugs in the treatment of MAT has generally been disappointing [<a href="#rid1">1,24</a>]. Additionally, administration of antiarrhythmic agents to acutely ill patients with renal and/or hepatic dysfunction increases the risk of toxic reactions to these agents. There is, however, evidence of benefit with agents to control the ventricular heart rate, namely <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> and beta blockers.</p><p>Medical therapy for MAT is indicated only if MAT causes a sustained rapid ventricular response that causes or worsens myocardial ischemia, heart failure, peripheral perfusion, or oxygenation [<a href="#rid15">15,28</a>]. For patients with symptomatic MAT requiring ventricular rate control, we recommend therapy with <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> or a beta blocker  (<a class="graphic graphic_table graphicRef83358" href="/d/graphic/83358.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H754581"><span class="h3">Nondihydropyridine calcium channel blockers</span><span class="headingEndMark"> — </span>While both <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> can be effective agents for slowing AV nodal conduction and controlling ventricular heart rates, verapamil has been most commonly used in MAT, and the response in some cases suggests that triggered activity may initiate the arrhythmia. (See <a class="local">'Mechanisms'</a> above.)</p><p><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> decreases the ventricular rate by reducing the degree of atrial ectopy and/or by limiting the transmission of beats through the AV node [<a href="#rid1">1,29-32</a>]. In an analysis of pooled data, verapamil lowered the ventricular rate by an average of 31 bpm, but only 43 percent of patients reverted to a sinus rhythm [<a href="#rid1">1</a>]. Furthermore, MAT may recur if verapamil is discontinued.</p><p>The following regimen, given with continuous ECG and blood pressure monitoring, has been suggested for intravenous <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>  (<a class="graphic graphic_table graphicRef83358" href="/d/graphic/83358.html" rel="external">table 1</a>) [<a href="#rid10">10</a>]. A 5 to 10 mg IV bolus over two minutes; if no response, an additional 10 mg IV bolus may be administered 15 to 30 minutes following the initial dose. A lower initial dose (eg, 2.5 mg IV) may be chosen in patients who are older or who have multiple comorbidities, in whom there are concerns about potential hypotension or other side effects. If MAT reverts to sinus rhythm, oral verapamil is given at an initial dose of 80 mg every six hours and subsequently titrated as blood pressure and heart rate allow (total daily dose range 120 to 480 mg).</p><p class="headingAnchor" id="H754588"><span class="h3">Beta blockers</span><span class="headingEndMark"> — </span>Beta blockers can suppress ectopic foci and decrease transmission through the AV node, thereby slowing the ventricular response. Their use in MAT has been limited because of the risk in patients with underlying heart failure or chronic obstructive pulmonary disease, particularly when bronchospasm is part of the picture. However, several studies showing a benefit have been performed, particularly with the relatively cardioselective agent <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> [<a href="#rid33">33-35</a>]. <a class="drug drug_general" data-topicid="9420" href="/d/drug information/9420.html" rel="external">Esmolol</a> and <a class="drug drug_general" data-topicid="9233" href="/d/drug information/9233.html" rel="external">acebutolol</a> have also been used in small numbers of patients [<a href="#rid36">36-38</a>].</p><p>The pooled data from the <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> studies revealed an average decrease in ventricular rate of 51 bpm, with 79 percent of patients reverting to sinus rhythm [<a href="#rid1">1</a>]. Side effects were few, but long-term therapy is required in approximately one-quarter of patients [<a href="#rid35">35</a>].</p><p>We use the following protocol for intravenous (IV) <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>  (<a class="graphic graphic_table graphicRef83358" href="/d/graphic/83358.html" rel="external">table 1</a>) [<a href="#rid34">34</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">Metoprolol</a> – 2.5 to 5 mg IV bolus over two to five minutes; if no response, an additional 2.5 to 5 mg IV bolus may be administered every 10 minutes to a total dose of 15 mg.</p><p></p><p>In patients who are unable to receive oral medications, subsequent doses of IV <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> can be administered every 4 to 6 hours with the patient in a monitored setting. An advantage of metoprolol is the ease of switching to an oral preparation (typically long-acting metoprolol at a dose of 50 mg once daily or short-acting metoprolol 25 mg twice daily, with titration as needed based on heart rate and blood pressure). Beta blockers should generally not be given to patients with acute decompensated heart failure, severe reactive pulmonary disease, hypotension, drug hypersensitivity, and a history or ECG showing greater than first-degree heart block, bifascicular block, or serious sinus node dysfunction (unless a pacemaker is implanted).</p><p class="headingAnchor" id="H22040828"><span class="h3">Precautions with verapamil and beta blockers</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">Verapamil</a> and beta blockers should <strong>not be given</strong> to patients with sinus node dysfunction or preexisting second- or third-degree block unless a temporary or permanent pacemaker has been implanted. Verapamil should be administered cautiously in patients with preexisting heart failure or hypotension as it has both negative inotropic and peripheral vasodilator activity, potentially leading to a reduction in blood pressure or even significant hypotension [<a href="#rid29">29,32</a>]. Beta blockers should also be administered cautiously in patients with acutely decompensated heart failure. Verapamil and beta blockers should either be avoided or used at lower doses and with caution in patients already treated with a beta blocker, verapamil or another calcium channel blocker, or <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>. (See  <a class="medical medical_review" href="/d/html/967.html" rel="external">"Major side effects of beta blockers"</a> and  <a class="medical medical_review" href="/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p class="headingAnchor" id="H23844633"><span class="h3">Which to use first: Calcium channel blocker or beta blocker?</span><span class="headingEndMark"> — </span>The decision to use a nondihydropyridine calcium channel blocker or a beta blocker is most often determined by the presence or absence of acute decompensated heart failure with reduced left ventricular ejection fraction and severe bronchospasm. We prefer <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a> before <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> in patients without these complications. In a randomized, double-blind study of 13 patients, the incidence of benefit was 89 percent with metoprolol versus 44 percent with verapamil [<a href="#rid28">28</a>]. (See  <a class="medical medical_review" href="/d/html/3461.html" rel="external">"Treatment and prognosis of heart failure with preserved ejection fraction", section on 'Secondary therapies'</a> and  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p>By contrast, we prefer to begin with <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a> (or <a class="drug drug_general" data-topicid="9365" href="/d/drug information/9365.html" rel="external">diltiazem</a>) in patients with severe bronchospasm. Beta blockers may be used cautiously in some patients with heart failure, but active bronchospasm is a contraindication. (See  <a class="medical medical_review" href="/d/html/121086.html" rel="external">"Primary pharmacologic therapy for heart failure with reduced ejection fraction", section on 'Beta blocker'</a>.)</p><p>In either case, repletion of electrolyte deficiencies (hypomagnesemia and hypokalemia) should occur simultaneously. (See <a class="local">'Magnesium and potassium repletion'</a> above.)</p><p class="headingAnchor" id="H754595"><span class="h2">Antiarrhythmic drugs</span><span class="headingEndMark"> — </span>For patients with symptomatic MAT that remains inadequately rate-controlled following treatment of the underlying disorder and initiation of rate controlling therapy, we do <strong>not</strong> use an antiarrhythmic drug. This is based on extensive literature showing a general lack of efficacy of standard antiarrhythmic drugs in treating MAT [<a href="#rid24">24</a>]. Ineffective drugs include <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, and <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, among others [<a href="#rid1">1</a>]. Digitalis also appears to have little benefit [<a href="#rid2">2,13</a>].</p><p><a class="drug drug_general" data-topicid="8548" href="/d/drug information/8548.html" rel="external">Ibutilide</a> has been used successfully to treat MAT in one older adult, but more experience with this drug is need [<a href="#rid39">39</a>]. Additionally, ibutilide should never be used in the presence of known or suspected hypokalemia or hypomagnesemia. (See  <a class="medical medical_review" href="/d/html/924.html" rel="external">"Therapeutic use of ibutilide"</a>.)</p><p class="headingAnchor" id="H754602"><span class="h2">DC cardioversion</span><span class="headingEndMark"> — </span>DC cardioversion has not proven effective in converting MAT into a sinus rhythm [<a href="#rid13">13,24,40</a>]. As such, we do <strong>not</strong> perform cardioversion for patients with symptomatic MAT that remains inadequately rate-controlled.</p><p class="headingAnchor" id="H754609"><span class="h2">Radiofrequency ablation</span><span class="headingEndMark"> — </span>Ablation of the AV node and the use of a permanent ventricular pacemaker is an option for patients with ongoing symptomatic MAT who do not respond to, or cannot tolerate, pharmacologic therapy. This procedure should rarely be required, because the vast majority of MAT episodes are brief and because the arrhythmia resolves with correction of the underlying abnormality [<a href="#rid15">15</a>]. To re-emphasize this, AV junction ablation resulting in creation of complete heart block necessitating permanent pacemaker implantation should not be performed for the purpose of making the ECG appear more normal. It should only be performed in order to improve cardiopulmonary function after proving that the arrhythmia is actually the cause of hemodynamic compromise.</p><p>Since most of the manifestations associated with MAT are due to the rapid ventricular rate, an alternative approach for rate control is radiofrequency modification of the AV junction, similar to the approach taken for rate control in atrial fibrillation. Ablation to cure MAT is rarely indicated and not likely to be effective given the underlying diffuse atrial abnormalities. Early data concerning radiofrequency modification of the AV node were encouraging, but modification of AV transmission without producing complete heart block is unreliable and rarely long-lasting.</p><p>AV node modification with ablation was evaluated in one study of 13 patients with chronic obstructive lung disease and medically refractory MAT who underwent AV junctional modification [<a href="#rid41">41</a>]. This procedure resulted in adequate control of the ventricular response rate in 84 percent of patients, and the rate was reduced from an average of 145 to 89 bpm. One patient developed complete heart block, and one patient had recurrent symptomatic MAT, requiring a second procedure. After a six-month follow-up, all patients with successful modification had an improved quality of life, a reduction in symptoms, and an increase in left ventricular ejection fraction. (See  <a class="medical medical_review" href="/d/html/1012.html" rel="external">"Atrial fibrillation: Atrioventricular node ablation"</a>.)</p><p class="headingAnchor" id="H1787617293"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H754616"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Multifocal atrial tachycardia (MAT) is an arrhythmia that can be seen in a variety of clinical disorders in adults, children, and infants. In addition to a heart rate &gt;100 beats per minute (bpm), the characteristic electrocardiographic (ECG) feature in MAT is variability in P-wave morphology, with three or more distinct P-wave morphologies. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients have similar ECG findings with multiple P-wave morphologies but do not meet criteria for tachycardia. The arrhythmia is called a multifocal atrial rhythm or wandering atrial pacemaker if the rate is between 60 and 100 bpm. (See <a class="local">'Terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>MAT is associated with significant lung disease in roughly 60 percent of cases and is identified in up to 20 percent of patients hospitalized for acute respiratory failure. MAT can also occur in the presence of coronary, valvular, hypertensive and other types of heart disease, particularly when associated with heart failure and/or underlying lung disease. (See <a class="local">'Associated clinical conditions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In most cases, the clinical manifestations of MAT differ from those of other tachyarrhythmias in that symptoms predominantly relate to the underlying precipitating illness rather than the arrhythmia. Patients have an irregular heart rate greater than 100 bpm, usually identified only during the physical exam by the health care provider, and they rarely present with symptoms of palpitations, presyncope, or syncope as the sole manifestation of MAT. (See <a class="local">'Clinical manifestations and diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The diagnosis of MAT can be suspected from the presence of an irregular rapid pulse and heartbeat on physical examination; however, the diagnosis cannot be confirmed without an ECG. A diagnosis of MAT requires the following be present on the ECG  (<a class="graphic graphic_waveform graphicRef127222" href="/d/graphic/127222.html" rel="external">waveform 1</a>) (see <a class="local">'Clinical manifestations and diagnosis'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Discrete P waves with at least <strong>three</strong> different morphologies (including the normal sinus P wave)</p><p class="bulletIndent2"><span class="glyph">•</span>An atrial rate greater than 100 bpm</p><p class="bulletIndent2"><span class="glyph">•</span>P waves which are separated by isoelectric intervals</p><p class="bulletIndent2"><span class="glyph">•</span>P-P intervals, P-R duration, and R-R intervals which vary</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Most episodes of MAT do not precipitate hemodynamic compromise or limiting symptoms. Thus, therapy in patients with MAT should be aimed at the inciting underlying disease. (See <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with MAT and associated hypokalemia or hypomagnesemia should undergo electrolyte repletion prior to the initiation of additional medical therapy for MAT. (See <a class="local">'Magnesium and potassium repletion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Medical therapy for MAT is indicated only if MAT causes a sustained rapid ventricular response that causes or worsens myocardial ischemia, heart failure, peripheral perfusion, or oxygenation. Options for medical therapy for patients with symptomatic MAT requiring ventricular rate control include nondihydropyridine calcium channel blockers and beta blockers. For patients without heart failure or bronchospasm, we suggest initial therapy with a beta blocker, usually <a class="drug drug_general" data-topicid="9645" href="/d/drug information/9645.html" rel="external">metoprolol</a>, before calcium channel blockers (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Conversely, for patients with severe bronchospasm, we suggest initial therapy with a nondihydropyridine calcium channel blocker, usually <a class="drug drug_general" data-topicid="10043" href="/d/drug information/10043.html" rel="external">verapamil</a>, rather than a beta blocker (<a class="grade" href="https://medilib.ir/uptodate/show/grade_6" rel="external">Grade 2C</a>). Beta blockers may be used cautiously in some patients with heart failure. (See <a class="local">'Pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extensive literature has shown a lack of efficacy of numerous standard antiarrhythmic drugs (including <a class="drug drug_general" data-topicid="9846" href="/d/drug information/9846.html" rel="external">quinidine</a>, <a class="drug drug_general" data-topicid="9813" href="/d/drug information/9813.html" rel="external">procainamide</a>, <a class="drug drug_general" data-topicid="9558" href="/d/drug information/9558.html" rel="external">lidocaine</a>, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, and <a class="drug drug_general" data-topicid="9360" href="/d/drug information/9360.html" rel="external">digoxin</a>) as well as electrical cardioversion in treating MAT. (See <a class="local">'Antiarrhythmic drugs'</a> above and <a class="local">'DC cardioversion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ablation of the atrioventricular (AV) node and the use of a permanent ventricular pacemaker is rarely indicated, and should be reserved for patients with ongoing symptomatic MAT who do not respond to or cannot tolerate pharmacologic therapy. (See <a class="local">'Radiofrequency ablation'</a> above.)</p><p></p><p class="headingAnchor" id="H2450277150"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Leonard Ganz, MD, FHRS, FACC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Kastor JA. Multifocal atrial tachycardia. N Engl J Med 1990; 322:1713.</a></li><li><a class="nounderline abstract_t">Shine KI, Kastor JA, Yurchak PM. Multifocal atrial tachycardia. Clinical and electrocardiographic features in 32 patients. N Engl J Med 1968; 279:344.</a></li><li><a class="nounderline abstract_t">Berlinerblau R, Feder W. Chaotic atrial rhythm. J Electrocardiol 1972; 5:135.</a></li><li><a class="nounderline abstract_t">Bisset GS 3rd, Seigel SF, Gaum WE, Kaplan S. Chaotic atrial tachycardia in childhood. Am Heart J 1981; 101:268.</a></li><li><a class="nounderline abstract_t">Gavrilescu, S, Luca, C . Chaotic atrial rhythm: Studies with His bundle electrography. Eur J Cardiol 1974; 2:153.</a></li><li class="breakAll">Glass L, Mackey MC. From Clocks to Chaos: The Rhythms of Life, Princeton University Press, Princeton, NJ 1988.</li><li><a class="nounderline abstract_t">Kothari SA, Apiyasawat S, Asad N, Spodick DH. Evidence supporting a new rate threshold for multifocal atrial tachycardia. Clin Cardiol 2005; 28:561.</a></li><li><a class="nounderline abstract_t">Yokoshiki H, Mitsuyama H, Watanabe M, Tsutsui H. Swallowing-induced multifocal atrial tachycardia originating from right pulmonary veins. J Electrocardiol 2011; 44:395.e1.</a></li><li><a class="nounderline abstract_t">Marchlinski FE, Miller JM. Atrial arrhythmias exacerbated by theophylline. Response to verapamil and evidence for triggered activity in man. Chest 1985; 88:931.</a></li><li><a class="nounderline abstract_t">Levine JH, Michael JR, Guarnieri T. Treatment of multifocal atrial tachycardia with verapamil. N Engl J Med 1985; 312:21.</a></li><li><a class="nounderline abstract_t">Santos-Ocampo CD, Sadaniantz A, Elion JL, et al. Echocardiographic assessment of the cardiac anatomy in patients with multifocal atrial tachycardia: a comparison with atrial fibrillation. Am J Med Sci 1994; 307:264.</a></li><li><a class="nounderline abstract_t">Engel TR, Radhagopalan S. Treatment of multifocal atrial tachycardia by treatment of pulmonary insufficiency: or is it vice versa? Chest 2000; 117:7.</a></li><li><a class="nounderline abstract_t">Wang K, Goldfarb BL, Gobel FL, Richman HG. Multifocal atrial tachycardia. Arch Intern Med 1977; 137:161.</a></li><li><a class="nounderline abstract_t">Lipson MJ, Naimi S. Multifocal atrial tachycardia (chaotic atrial tachycardia). Clinical associations and significance. Circulation 1970; 42:397.</a></li><li><a class="nounderline abstract_t">Goudis CA, Konstantinidis AK, Ntalas IV, Korantzopoulos P. Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease. Int J Cardiol 2015; 199:264.</a></li><li><a class="nounderline abstract_t">Hudson LD, Kurt TL, Petty TL, Genton E. Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction. Chest 1973; 63:661.</a></li><li><a class="nounderline abstract_t">Levine JH, Michael JR, Guarnieri T. Multifocal atrial tachycardia: a toxic effect of theophylline. Lancet 1985; 1:12.</a></li><li><a class="nounderline abstract_t">Antwi-Amoabeng D, Beutler BD, Singh S, et al. Association between electrocardiographic features and mortality in COVID-19 patients. Ann Noninvasive Electrocardiol 2021; 26:e12833.</a></li><li><a class="nounderline abstract_t">Tutar E, Kaya A, Güleç S, et al. Echocardiographic evaluation of left ventricular diastolic function in chronic cor pulmonale. Am J Cardiol 1999; 83:1414.</a></li><li><a class="nounderline abstract_t">Moustapha A, Kaushik V, Diaz S, et al. Echocardiographic evaluation of left-ventricular diastolic function in patients with chronic pulmonary hypertension. Cardiology 2001; 95:96.</a></li><li><a class="nounderline abstract_t">Iseri LT, Fairshter RD, Hardemann JL, Brodsky MA. Magnesium and potassium therapy in multifocal atrial tachycardia. Am Heart J 1985; 110:789.</a></li><li><a class="nounderline abstract_t">Phillips J, Spano J, Burch G. Chaotic atrial mechanism. Am Heart J 1969; 78:171.</a></li><li><a class="nounderline abstract_t">Chung EK. Appraisal of multifocal atrial tachycardia. Br Heart J 1971; 33:500.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 2016; 133:e506.</a></li><li><a class="nounderline abstract_t">Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.</a></li><li><a class="nounderline abstract_t">McCord JK, Borzak S, Davis T, Gheorghiade M. Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease. Am J Cardiol 1998; 81:91.</a></li><li><a class="nounderline abstract_t">Strickberger SA, Miller CB, Levine JH. Multifocal atrial tachycardia from electrolyte imbalance. Am Heart J 1988; 115:680.</a></li><li><a class="nounderline abstract_t">Parrillo, JE . Treating multifocal atrial tachycardia (MAT) in a critical care unit: New data regarding verapamil and metoprolol. Update Crit Care Med 1987; 2:1, 3.</a></li><li><a class="nounderline abstract_t">Schettini B, Katz S, Zeldis SM. Verapamil in tachycardia therapy. Chest 1986; 89:616.</a></li><li><a class="nounderline abstract_t">Mukerji V, Alpert MA, Diaz-Arias M, Sanfelippo JF. Termination and suppression of multifocal atrial tachycardia with verapamil. South Med J 1987; 80:269.</a></li><li><a class="nounderline abstract_t">Salerno DM, Anderson B, Sharkey PJ, Iber C. Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment. Ann Intern Med 1987; 107:623.</a></li><li><a class="nounderline abstract_t">Hazard PB, Burnett CR. Verapamil in multifocal atrial tachycardia. Hemodynamic and respiratory changes. Chest 1987; 91:68.</a></li><li><a class="nounderline abstract_t">Hanau, SP, Solar, et al. Metoprolol in the treatment of multifocal atrial tachycardia. Cardiovasc Rev Rep 1984; 5:1182.</a></li><li><a class="nounderline abstract_t">Arsura EL, Solar M, Lefkin AS, et al. Metoprolol in the treatment of multifocal atrial tachycardia. Crit Care Med 1987; 15:591.</a></li><li><a class="nounderline abstract_t">Hazard PB, Burnett CR. Treatment of multifocal atrial tachycardia with metoprolol. Crit Care Med 1987; 15:20.</a></li><li><a class="nounderline abstract_t">Byrd RC, Sung RJ, Marks J, Parmley WW. Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias. J Am Coll Cardiol 1984; 3:394.</a></li><li><a class="nounderline abstract_t">Aronow WS, Van Camp S, Turbow M, et al. Acebutolol in supraventricular arrhythmias. Clin Pharmacol Ther 1979; 25:149.</a></li><li><a class="nounderline abstract_t">Williams DO, Tatelbaum R, Most AS. Effective treatment of supraventricular arrhythmias with acebutolol. Am J Cardiol 1979; 44:521.</a></li><li><a class="nounderline abstract_t">Pierce WJ, McGroary K. Multifocal atrial tachycardia and Ibutilide. Am J Geriatr Cardiol 2001; 10:193.</a></li><li><a class="nounderline abstract_t">Kones RJ, Phillips JH, Hersh J. Mechanism and management of chaotic atrial mechanism. Cardiology 1974; 59:92.</a></li><li><a class="nounderline abstract_t">Ueng KC, Lee SH, Wu DJ, et al. Radiofrequency catheter modification of atrioventricular junction in patients with COPD and medically refractory multifocal atrial tachycardia. Chest 2000; 117:52.</a></li></ol></div><div id="topicVersionRevision">Topic 901 Version 28.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2188131" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Multifocal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5662166" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Multifocal atrial tachycardia. Clinical and electrocardiographic features in 32 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5033407" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Chaotic atrial rhythm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7468435" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Chaotic atrial tachycardia in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Chaotic atrial rhythm: Studies with His bundle electrography</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Chaotic atrial rhythm: Studies with His bundle electrography</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16405199" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evidence supporting a new rate threshold for multifocal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21353237" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Swallowing-induced multifocal atrial tachycardia originating from right pulmonary veins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4064786" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Atrial arrhythmias exacerbated by theophylline. Response to verapamil and evidence for triggered activity in man.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3964904" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Treatment of multifocal atrial tachycardia with verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8160719" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Echocardiographic assessment of the cardiac anatomy in patients with multifocal atrial tachycardia: a comparison with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631189" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of multifocal atrial tachycardia by treatment of pulmonary insufficiency: or is it vice versa?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/836113" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Multifocal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5451226" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Multifocal atrial tachycardia (chaotic atrial tachycardia). Clinical associations and significance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26218181" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Electrocardiographic abnormalities and cardiac arrhythmias in chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4122207" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Arrhythmias associated with acute respiratory failure in patients with chronic airway obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2856947" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Multifocal atrial tachycardia: a toxic effect of theophylline.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33742501" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Association between electrocardiographic features and mortality in COVID-19 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10235106" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Echocardiographic evaluation of left ventricular diastolic function in chronic cor pulmonale.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11423714" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Echocardiographic evaluation of left-ventricular diastolic function in patients with chronic pulmonary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4050650" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Magnesium and potassium therapy in multifocal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4894486" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Chaotic atrial mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5557461" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Appraisal of multifocal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26399663" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462615" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Usefulness of intravenous magnesium for multifocal atrial tachycardia in patients with chronic obstructive pulmonary disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3344663" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Multifocal atrial tachycardia from electrolyte imbalance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treating multifocal atrial tachycardia (MAT) in a critical care unit: New data regarding verapamil and metoprolol</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3956290" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Verapamil in tachycardia therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3810231" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Termination and suppression of multifocal atrial tachycardia with verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3662276" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intravenous verapamil for treatment of multifocal atrial tachycardia with and without calcium pretreatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3792087" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Verapamil in multifocal atrial tachycardia. Hemodynamic and respiratory changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Metoprolol in the treatment of multifocal atrial tachycardia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3568727" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Metoprolol in the treatment of multifocal atrial tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3792010" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment of multifocal atrial tachycardia with metoprolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6141193" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Safety and efficacy of esmolol (ASL-8052: an ultrashort-acting beta-adrenergic blocking agent) for control of ventricular rate in supraventricular tachycardias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/365429" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acebutolol in supraventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/382821" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Effective treatment of supraventricular arrhythmias with acebutolol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11455238" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Multifocal atrial tachycardia and Ibutilide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4434363" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Mechanism and management of chaotic atrial mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631199" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Radiofrequency catheter modification of atrioventricular junction in patients with COPD and medically refractory multifocal atrial tachycardia.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
